866-997-4948(US-Canada Toll Free)

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Oncology

No. of Pages : 447 Pages


Global Markets Directs, \'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM). Glioblastoma Multiforme (GBM) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Glioblastoma Multiforme (GBM).
  • A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Glioblastoma Multiforme (GBM) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
Introduction 6
Glioblastoma Multiforme (GBM) Overview 7
Therapeutics Development 8
Glioblastoma Multiforme (GBM) Therapeutics under Development by Companies 10
Glioblastoma Multiforme (GBM) Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 21
Mid Clinical Stage Products 22
Early Clinical Stage Products 23
Discovery and Pre-Clinical Stage Products 24
Glioblastoma Multiforme (GBM) Therapeutics - Products under Development by Companies 25
Glioblastoma Multiforme (GBM) Therapeutics - Products under Investigation by Universities/Institutes 33
Companies Involved in Glioblastoma Multiforme (GBM) Therapeutics Development 35
Glioblastoma Multiforme (GBM) - Therapeutics Assessment 113
Drug Profiles 121
Glioblastoma Multiforme (GBM) Therapeutics - Drug Profile Updates 339
Glioblastoma Multiforme (GBM) Therapeutics - Discontinued Products 415
Glioblastoma Multiforme (GBM) Therapeutics - Dormant Products 416
Glioblastoma Multiforme (GBM) - Product Development Milestones 419

Appendix 430

List of Table


Number of Products Under Development for Glioblastoma Multiforme (GBM), H2 2013 24
Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2013 25
Number of Products under Development by Companies, H2 2013 27
Number of Products under Development by Companies, H2 2013 (Contd..1) 28
Number of Products under Development by Companies, H2 2013 (Contd..2) 29
Number of Products under Development by Companies, H2 2013 (Contd..3) 30
Number of Products under Development by Companies, H2 2013 (Contd..4) 31
Number of Products under Development by Companies, H2 2013 (Contd..5) 32
Number of Products under Development by Companies, H2 2013 (Contd..6) 33
Number of Products under Investigation by Universities/Institutes, H2 2013 35
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 36
Comparative Analysis by Late Stage Development, H2 2013 37
Comparative Analysis by Mid Clinical Stage Development, H2 2013 38
Comparative Analysis by Early Clinical Stage Development, H2 2013 39
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 40
Products under Development by Companies, H2 2013 41
Products under Development by Companies, H2 2013 (Contd..1) 42
Products under Development by Companies, H2 2013 (Contd..2) 43
Products under Development by Companies, H2 2013 (Contd..3) 44
Products under Development by Companies, H2 2013 (Contd..4) 45
Products under Development by Companies, H2 2013 (Contd..5) 46
Products under Development by Companies, H2 2013 (Contd..6) 47
Products under Development by Companies, H2 2013 (Contd..7) 48
Products under Investigation by Universities/Institutes, H2 2013 49
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 50
Johnson & Johnson, H2 2013 51
F. Hoffmann-La Roche Ltd., H2 2013 52
Amgen Inc., H2 2013 53
Sanofi-Aventis, H2 2013 54
AstraZeneca PLC, H2 2013 55
Eli Lilly and Company, H2 2013 56
Genentech, Inc., H2 2013 57
Antigenics, Inc., H2 2013 58
MedImmune LLC, H2 2013 59
Lentigen Corporation, H2 2013 60
Sangamo BioSciences, Inc., H2 2013 61
Plexxikon Inc., H2 2013 62
Celltrion, Inc., H2 2013 63
ZIOPHARM Oncology, Inc., H2 2013 64
Novartis AG, H2 2013 65
Actelion Ltd, H2 2013 66
Biocon Limited, H2 2013 67
Les Laboratoires Servier, H2 2013 68
Nippon Shinyaku Co., Ltd., H2 2013 69
Pfizer Inc., H2 2013 70
Cell Therapeutics, Inc., H2 2013 71
Exelixis, Inc., H2 2013 72
Aduro BioTech, H2 2013 73
EpiCept Corporation, H2 2013 74
Celldex Therapeutics, Inc., H2 2013 75
ImmunoCellular Therapeutics, Ltd., H2 2013 76
Lixte Biotechnology Holdings, Inc., H2 2013 77
Basilea Pharmaceutica Ltd., H2 2013 78
Northwest Biotherapeutics, Inc., H2 2013 79
Oncothyreon Inc, H2 2013 80
Peregrine Pharmaceuticals, Inc., H2 2013 81
CytRx Corporation, H2 2013 82
Pharmacyclics, Inc., H2 2013 83
Transgene SA, H2 2013 84
Prana Biotechnology Limited, H2 2013 85
Green Cross Corporation, H2 2013 86
Innocell Corporation, H2 2013 87
Panacea Biotec Limited, H2 2013 88
Rexahn Pharmaceuticals, Inc., H2 2013 89
Nanobiotix, H2 2013 90
Spectrum Pharmaceuticals, Inc., H2 2013 91
Fusion Antibodies Ltd, H2 2013 92
Upsher-Smith Laboratories, Inc., H2 2013 93
Nerviano Medical Sciences S.r.l., H2 2013 94
immatics biotechnologies GmbH, H2 2013 95
Apogenix GmbH, H2 2013 96
EnGeneIC Ltd, H2 2013 97
AGY Therapeutics, Inc., H2 2013 98
Diffusion Pharmaceuticals LLC, H2 2013 99
MacroGenics, Inc., H2 2013 100
Deciphera Pharmaceuticals, LLC, H2 2013 101
Stemline Therapeutics, Inc., H2 2013 102
BioCancell Therapeutics, Inc., H2 2013 103
Axelar AB, H2 2013 104
Advenchen Laboratories, LLC, H2 2013 105
Viral Genetics, Inc., H2 2013 106
NOXXON Pharma AG, H2 2013 107
ImmunoVaccine Technologies Inc., H2 2013 108
Globeimmune, Inc., H2 2013 109
ChemoCentryx, Inc., H2 2013 110
TVAX Biomedical, LLC, H2 2013 111
Biovista Inc., H2 2013 112
Sirnaomics, Inc., H2 2013 113
Oncovir, Inc., H2 2013 114
TRACON Pharmaceuticals, Inc., H2 2013 115
Nexgenix Pharmaceuticals, LLC, H2 2013 116
Georgia Tech Research Corporation, H2 2013 117
Regulus Therapeutics Inc., H2 2013 118
CLL Pharma, H2 2013 119
DiscoveryBiomed, Inc., H2 2013 120
Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2013 121
GreenPeptide Co., Ltd., H2 2013 122
Incuron, H2 2013 123
FCB-Pharmicell Co.,Ltd., H2 2013 124
TAU Therapeutics, LLC, H2 2013 125
EirGen Pharma Ltd., H2 2013 126
CytoVac A/S, H2 2013 127
Ampio Pharmaceuticals, Inc., H2 2013 128
Assessment by Monotherapy Products, H2 2013 129
Assessment by Combination Products, H2 2013 130
Assessment by Stage and Route of Administration, H2 2013 133
Assessment by Stage and Molecule Type, H2 2013 136
Glioblastoma Multiforme (GBM) Therapeutics - Drug Profile Updates 355
Glioblastoma Multiforme (GBM) Therapeutics - Discontinued Products 431
Glioblastoma Multiforme (GBM) Therapeutics - Dormant Products 432
Glioblastoma Multiforme (GBM) Therapeutics - Dormant Products (Contd..2) 433
Glioblastoma Multiforme (GBM) Therapeutics - Dormant Products (Contd..3) 434

List of Chart


Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2013 24
Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2013 25
Products under Development by Companies, H2 2013 26
Products under Investigation by Universities/Institutes, H2 2013 34
Late Stage Products, H2 2013 37
Mid Clinical Stage Products, H2 2013 38
Early Clinical Stage Products, H2 2013 39
Discovery and Pre-Clinical Stage Products, H2 2013 40
Assessment by Monotherapy Products, H2 2013 129
Assessment by Combination Products, H2 2013 130
Assessment by Route of Administration, H2 2013 131
Assessment by Stage and Route of Administration, H2 2013 132
Assessment by Molecule Type, H2 2013 134
Assessment by Stage and Molecule Type, H2 2013 135

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *